Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Decade in review—HCV

Hepatitis C therapy—a fast and competitive race

Nature Reviews Gastroenterology & Hepatology volume 11, pages 644–645 (2014)Cite this article

Subjects

The past 10 years have witnessed incredible developments in the treatment of hepatitis C. From an era in which the standard of care was PEG-IFN and ribavirin back in 2004, various interferon-free regimens with direct-acting antivirals are now available or will be soon. Here, major milestones in the hepatitis C treatment revolution are outlined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lange, C. M., Jacobson, I. M., Rice, C. M. & Zeuzem, S. Emerging therapies for the treatment of hepatitis C. EMBO Mol. Med. 6, 4–15 (2014).

    Article  CAS  Google Scholar 

  2. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189 (2003).

    Article  CAS  Google Scholar 

  3. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).

    Article  CAS  Google Scholar 

  4. Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013).

    Article  CAS  Google Scholar 

  5. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012).

    Article  CAS  Google Scholar 

  6. Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889–1898 (2014).

    Article  Google Scholar 

  7. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483–1493 (2014).

    Article  CAS  Google Scholar 

  8. Feld, J. J. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594–1603 (2014).

    Article  CAS  Google Scholar 

  9. Zeuzem, S. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1604–1614 (2014).

    Article  CAS  Google Scholar 

  10. Zeuzem, S. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369, 630–639 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, J. W. Goethe University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany

    Stefan Zeuzem

Authors
  1. Stefan Zeuzem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Zeuzem.

Ethics declarations

Competing interests

The author acts as a consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Idenix, Janssen, Merck, Novartis, Roche, Santaris and Vertex. He is a member of the speakers' bureau for Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Merck and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeuzem, S. Hepatitis C therapy—a fast and competitive race. Nat Rev Gastroenterol Hepatol 11, 644–645 (2014). https://doi.org/10.1038/nrgastro.2014.164

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.164

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing